Small Molecules

28 Feb 2017 Vycellix and Moffitt Cancer Center Announce a Collaborative Research Study to Evaluate Novel Product Candidates for Improving Adoptive Cell Immunotherapies for Cancer
28 Feb 2017 Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes
28 Feb 2017 AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C
28 Feb 2017 BioCryst Reports Positive Interim Results from its APeX-1 Trial
28 Feb 2017 NoNO Inc Initiates Phase III Study of NA-1 for Acute Ischemic Stroke
28 Feb 2017 FDA approves once-daily Qtern (dapagliflozin and saxagliptin) tablets for adults with type-2 diabetes
27 Feb 2017 Merck’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in Pivotal Phase 3 Study
24 Feb 2017 Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451
24 Feb 2017 Novartis receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-positive non-small cell lung cancer (NSCLC) patients
24 Feb 2017 ZS-9 (sodium zirconium cyclosilicate) receives positive CHMP opinion for the treatment of hyperkalaemia
23 Feb 2017 Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
23 Feb 2017 Corbus Pharmaceuticals Announces Preclinical Data Demonstrating JBT-101 Reduces Inflammation in Alveolar Macrophages from Cystic Fibrosis Patients
23 Feb 2017 Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin™ in Patients with Metastatic Triple Negative Breast Cancer
23 Feb 2017 Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia
23 Feb 2017 Aeolus Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers
23 Feb 2017 FDA Expands Indication for REVLIMID® (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT)
23 Feb 2017 Positive results for Relvar® Ellipta® lung function study in patients with well-controlled asthma
23 Feb 2017 Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
22 Feb 2017 Kalytera Therapeutics Announces Encouraging Results of a Phase 2a Clinical Study for the Treatment of Acute Graft versus Host Disease
22 Feb 2017 Lantheus Holdings and GE Healthcare Announce the Signing of a Term Sheet for Worldwide Development and Commercialization of Flurpiridaz F 18
22 Feb 2017 Trevena Announces Positive Top-line Results from Two Phase 3 Pivotal Efficacy Studies of Intravenous Oliceridine in Moderate-to-Severe Acute Pain 2/21/17
21 Feb 2017 Loxo Oncology Announces Completion of Clinical Trial Enrollment for Larotrectinib NDA Primary Efficacy Analysis
21 Feb 2017 Boston Biomedical Initiates CanStem111P: A Global Phase 3 Study Investigating Cancer Stemness Inhibitor Napabucasin in Patients With Metastatic Pancreatic Cancer
21 Feb 2017 Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer
20 Feb 2017 Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing